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ABSTRACT 
Two different Janus Kinase (JAK) inhibitors – baricitinib and tofacitinib – are effective and 
licensed in active rheumatoid arthritis (RA). There have been recent concerns about potential 
thromboembolic risks with these drugs. 
 
Concerns about baricitinib focus on clinical trial findings. Using all publically available data 
we estimate thromboembolic risks are approximately 5 events per 1,000 patient years with 
4mg baricitinib daily. Concerns about tofacitinib have been raised by analyses of the Federal 
Drug Administration Adverse Event Reporting System (FAERs). These show some evidence 
of increased risks of pulmonary thrombosis, though not pulmonary embolism or venous 
thrombosis.  
 
Many observational studies show thromboembolic events are increased in RA. In RA 
patients, there are between 3 to 8 thromboembolic events per 1,000 patient years compared 
with 1 to 4 events per 1,000 patient years in the general population and non-RA controls. 
Disease-modifying anti-rheumatic drugs and biologic treatments seem to not increase the risk 
of thromboembolic events, but corticosteroids may do so.  
 
In the short-term, full details of thromboembolic events in trials of JAK inhibitors need to be 
published. As the numbers of thromboembolic events will be small and patients enrolled in 
trials are not representative of all RA patients who may receive JAK inhibitors, this 
information is unlikely to provide definitive answers. Consequently, in the longer-term large 
observational studies are needed to accurately quantify thromboembolic risks attributable to 
JAK inhibitors and other drugs used to treat RA, and differentiate these from risks 
attributable to RA itself and its comorbidities.  
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Janus Kinase (JAK) Inhibitors In Rheumatoid Arthritis 
Two Janus Kinase (JAK) inhibitors are currently used to treat patients with active rheumatoid 
arthritis (RA). These comprise Bariticinib, which is approved in Europe, Japan and some 
other countries, and Tofacitinib, which is also approved in the United States. JAK inhibitors 
are considered potentially important innovations, as they represent rapidly-acting, oral 
treatments, which are effective in RA and other inflammatory diseases [1,2]. Tofacitinib and 
baricitinib are likely to be the first in a range of different JAK inhibitors, which are at various 
stages of their development [3]. 
 
Baricitinib And Thromboembolism 
In August 2017, the Summary of Product Characteristics (SPCs) for baricitinib was revised to 
include a warning that deep venous thrombosis and pulmonary embolism have been reported 
in patients receiving baricitinib. The SPC recommended it should be used with caution in 
patients with risk factors for deep venous thrombosis and pulmonary embolus, such as older 
age, obesity, a medical history of these disorders, recent surgery or immobilisation. 
 
Our review places this potential risk into clinical context. Firstly, we have reviewed available 
evidence about thromboembolic events with baricitinib. Secondly, we have assessed whether 
there are any thromboembolic risks with other JAK inhibitors. Thirdly we have outlined the 
relationship between thromboembolism and RA and other medications. Finally, we have 
considered the challenges assessing unexpected adverse events with new RA treatments. 
 
Overall Risks and Benefits of JAK Inhibitors in Rheumatoid Arthritis 
The potential thromboembolic risks with baricitinib need to be considered in relation to its 
overall efficacy and toxicity in RA. There have been seven Phase 2 and Phase 3 trials in 
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patients with active RA. A Bayesian network meta-analysis [4] evaluated efficacy in the 
3,461 patients enrolled to these trials. Significantly more patients achieved the primary 
outcome - American College of Rheumatology 20 (ACR20) response rates – with baricitinib 
4 mg combined with methotrexate or other disease-modifying anti-rheumatic drugs 
(DMARDs) than controls. The odds ratio (OR) for achieving an ACR20 was 3.13 (95% CI 
2.32-4.33), which is clinically important. Non-systematic reviews are equally supportive 
about its efficacy in active RA [5,6].  
 
Data about baricitinib safety is also encouraging. The Bayesian systematic review reported 
that the rates of treatment-emergent adverse events were similar between baricitinib and 
controls [4]. Its relative safety has been confirmed in non-systematic reviews [5,6], an 
extension study of one of the main trials [7], and an integrated analysis of all trials [8].  
 
One other JAK inhibitor is licensed for treating active RA, tofacitinib, which has been 
approved more widely including North America. There is similar strong clinical trial 
evidence showing it is effective with acceptable safety; these have been collated in systematic 
and non-systematic reviews [9-12]. Although no head-to-head trials directly compare 
baricitinib with tofacitinib the drugs appear broadly comparable in efficacy and toxicity. 
There is one other licensed JAK inhibitor – ruxolitinib – used in myelofibrosis and 
polycythaemia rubra vera but not in RA.  
 
An overview of adverse events with JAK inhibitors in RA [13] highlighted risks of serious 
and opportunistic infections, particularly herpes zoster. However, neither this review, nor the 
various reports and reviews of JAK inhibitors in RA have addressed thromboembolic risks.  
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Current Evidence About Baricitinib And Thromboembolism 
The detailed information about efficacy and overall toxicity contrasts with limited data about 
possible thromboembolic risks within the public domain. Publications describing the phase 2 
and phase 3 trials contain some information. Six trials have been published in full [14-19]; 
the first trial published only as a meeting abstract contained few details about adverse events 
[20]. Thromboembolic events, deaths and serious adverse events in these six trials are 
summarised in Table 1. Three thromboembolic events were reported in the six trials: one 
pulmonary embolus resulted in the death of a control patient; one patient with a pulmonary 
embolus and another with thrombophlebitis were receiving 4mg baricitinib and neither event 
was fatal.  Similar data is provided by the Assessment Report from the European Medicines 
Agency [21].  
 
Finally, the pharmaceutical companies manufacturing baricitinib have provided a briefing 
document outlining the thromboembolic risks with baricitinib [22]. This document notes that 
seven phase 2 and phase 3 trials have been completed, with thromboembolic events occurring 
in five patients receiving baricitinib during the control period of two of the trials. It also states 
that “although an imbalance was observed during the placebo controlled period of the RA 
clinical trials, the rate of these events in the overall baricitinib clinical program was 
consistent with that seen among the general population of treated RA patients”. 
 
There is insufficient clarity in the publically available data to reach a definitive conclusion 
about the thromboembolic risks with baricitinib in RA. However, it is possible to provide an 
estimate of its potential magnitude. The manufacturers have stated 5 patients had a 
thromboembolic event whilst receiving 4mg baricitinib in the randomised phase of the trials. 
Over 1,300 patients were randomised to this treatment but not all received 12-months of 
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therapy; there are about 1,000 patient years follow-up at this dosage. Consequently, the risks 
of developing thromboembolism with 4mg baricitinib in patients with active RA appears to 
be in the region of 5 cases per 1,000 patient years. In controls, there is only definite evidence 
of one patient with thromboembolism. The numbers of controls in these trials is similar 
giving a rate in the region of 1 case per 1,000 patient years, which is below that reported in 
RA cohorts. The small numbers of patients with thromboembolism means this level of 
difference between groups will not reach statistical significance. It is also important to realise 
that, as is shown below in the observational studies, the risks of thromboembolism in patients 
receiving baracitinib is similar to that which is expected in people with active RA. 
 
Other JAK Inhibitors and Thromboembolism 
There is very little information about thromboembolic risks in the tofacitinib trials in RA. Its 
overall risks of deaths and serious adverse events from a recent systematic review [23] is 
summarised in Table 1. However, potentially important new information is available from 
analyses of the Federal Drug Administration Adverse Event Reporting System (FAERs). An 
assessment by Verden et al [24] has evaluated adverse events reported for two formulations 
of tofacitinib and ruxolitinib.  FAERS had 18 unique cases of pulmonary thrombosis for 
tofacitinib, 9 cases for ruxolitinib, and 3 cases for tofacitinib XR in which reporters identified 
these medications as the “Primary Suspect” drug. Sixteen of the 18 reported cases with 
tofacitinib were admitted to hospital. The Reporting Odds Ratio for pulmonary thrombosis 
was 2.46 (95% confidence intervals 1.55, 3.91) for tofacitinib; 1.46 (0.76, 2.80) for 
ruxolitinib; and 2.48 (0.80, 7.71) for tofacitinib XR. It is important to realise that post-
marketing surveillance has several limitations in assessing risks. In particular new treatments 
are often given to patients with the worst forms of disease who have failed many previous 
treatments. It is possible such patients will have increased risks of thromboembolic diseases 
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irrespective of any treatment effects. When biologics were introduced prospective 
international registers were established to assess long-term treatment risks, but this has not 
been done to the same extent with JAK inhibitors. 
 
Assessing the implications of this finding by itself is challenging. Pulmonary thrombosis 
occurs with some rare cardiac disorders [25] and vascular diseases like Behcet’s syndrome 
[26]. There are historical reports of pulmonary thromboses superimposed upon prior 
pulmonary emboli [27]. Finally, some reports mix the terms pulmonary thrombosis and 
pulmonary embolism [28]. It is impossible to know whether some or all of these different 
factors are involved in the report from Verden et al. However, as most of the patients with 
pulmonary thromboses were admitted to hospital the diagnostic classification is likely to be 
based on expert assessments.  
 
Finally, thromboembolism has been reported in a Phase 2 trial of another JAK inhibitor in 
RA [29]. This 12-week trial had two patients with pulmonary embolism out of 276 enrolled, 
both of whom were receiving different doses of the novel JAK inhibitor. 
 
Thromboembolism and Rheumatoid Arthritis 
The relationship between RA and thromboembolism has been extensively studied over the 
last decade. Observational studies have evaluated thromboembolic risks for RA patients in 
general, some sub-sets of RA patients such as rheumatoid factor positive patients, and 
patients taking some anti-rheumatic drugs. However, the studies do not give a comprehensive 
assessment of thromboembolic risks with treatment. Comparative data about risks from 
published studies is provided in Table 2. An early indication for a link was the observational 
study by Matta et al [30]. They evaluated thromboembolism in patients discharged from 
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short-stay hospitals in the United States between 1979 and 2005 who did not have surgery. 
Almost 5 million RA patients and nearly one billion controls were studied. Overall 0.85% of 
RA patients had a pulmonary embolus compared with 0.38% of controls.  Deep venous 
thrombosis was diagnosed in 1.64% RA patients and 0.86% controls. In this study patients 
with RA had approximately double the thromboembolic risks. 
 
A similar magnitude of risk was reported within the Rochester cohort of RA patients by 
Liang et al [31]. Their retrospective medical record review evaluated 609 RA patients 
followed over a decade or longer; the 30-year cumulative incidence rate of thromboembolic 
events was 7.2% compared to a risk of 3.5% in non-RA controls.  
 
Several subsequent studies further evaluated this relationship [32-36]. Systematic reviews in 
RA [37] and other inflammatory rheumatic diseases [38] have combined the findings of these 
various studies. In RA, Ungprasert [37] evaluated 9 observational studies. The pooled risk 
ratios of venous thrombosis and pulmonary embolism in RA patients compared with non-RA 
controls was 2.08 (95 % confidence interval (CI) 1.75–2.47) and 2.17 (95 % CI 2.05–2.31), 
respectively. Risks were consistently increased across cohort, case–control, and cross- 
sectional studies. Lee and Pope [36] reported similar increased risks in 10 studies of RA 
patients with comparable high-risks in other inflammatory rheumatic diseases. More recent 
studies confirm the increased risk of thromboembolic disease in RA [39,40].  
 
Meyer-Olesen et al [41] found high rheumatoid factor levels are a risk factor for deep venous 
thrombosis. They studied 54,628 participants from the Copenhagen City Heart Study. During 
368,381 person-years, 670 individuals developed deep venous thrombosis. Individuals with 
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increased concentrations of rheumatoid factor had an up to 3-fold increased long-term risk 
and up to 9-fold increased 1-year risk.  
 
Thromboembolism Risk with Biologics and Conventional DMARDs 
Three case series reported links between thromboembolic events and treatment with tumour 
necrosis factor inhibitors [42-44]. A review suggested an immune-mediated mechanism of 
action [44]. Kim et al [40] completed a population-based cohort study based on USA 
insurance claims data. They analysed nearly 40,000 treatment episodes in nearly 30,000 RA 
patients. Hospitalisation for thromboembolism occurred in 5.5 per 1,000 person-years in 
biologic DMARD initiators and 4.4 in non-biologic DMARD initiators. The hazard ratio for 
thromboembolism in biologic DMARD initiators was highest in the first 180 days compared 
to non-biologic DMARD initiators at 2.48 (95% CI 1.14-5.39). They found no evidence that 
starting methotrexate without a biologic DMARD had an effect on thromboembolism risk.  
 
In contrast, Davies et al [46] reported negative findings after evaluating data from the British 
Society for Rheumatology Biologics Register. They compared thromboembolic events in 
11,881 RA patients starting any of the currently available tumour necrosis factor inhibitors 
(etanercept, infliximab or adaliumumab) with 3,673 patients treated with conventional 
DMARDs. They identified 196 first thromboembolic events. There was no difference in the 
rates of thromboembolic events between groups (adjusted hazard ratio 0.8; 95% CI 0.5-1.5). 
With all these observational studies a variety of sources of bias exist, including channelling 
bias in which “sicker” patients get newer treatments.  
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Non-Steroidal Anti-Inflammatory Drugs, Oral Corticosteroids and Thromboembolism 
A prospective cohort study by Huerta et al [47], which involved a nested case-control 
analysis using the General Practice Research Database, evaluated thromboembolism risks in 
patients using corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs). 
Thromboembolism was newly diagnosed in 6,550 patients. There were 10,000 matched 
controls. The cases and controls had a range of comorbid conditions; fewer than 3% had RA. 
The odds of having a pulmonary embolus increased with NSAIDs (odds ratio 1.85; 95% CI 
1.65-2.10), particularly when treatment was started in the last 30 days. Risks were also 
increased by taking oral corticosteroids (odds ratio 3.05; 95% CI 2.51-3.69), with the risk 
also greatest in treatment started in the last 30 days.  
 
Risks with NSAIDs were subsequently evaluated in a systematic review by Ungprasert et al 
[48]. Six cohort and case-control studies were indentified, in which 21,401 thromboembolic 
events were evaluated. The pooled risk ratio for thromboembolism in NSAID users was 1.80 
(95% CI 1.28-2.52). 
 
We have not found a comparable systematic review of thromboembolism with 
corticosteroids. However, recent observational studies suggest a relationship exists. A 
population-based case-control study by Johannesdottir et al [49] used national Danish 
databases. It compared 38,765 thromboembolism cases with 387,650 matched controls. 
Systemic glucocorticoids increased thromboembolic risks (adjusted incidence rate ratio 2.31; 
95% CI 2.18-2.45). Risks were highest in new users. Waljee et al [50] evaluated American 
national private insurance claims for adults aged 18 to 64 years continuously enrolled from 
2012 to 2014. In over one and a half million adults more than 20% had received at least one 
prescription for short term oral corticosteroids. Within 30 days of starting treatment 
11 
 
thromboembolism risks increased (incidence rate ratio 3.33; 95% CI 2.78-3.99). These rates 
increased with age.  
 
Relative Frequency of Thromboembolism in the General Population 
Table 2 provides information about thromboembolism risks (expressed as the number of 
events per 1,000 patient years) in the general population [51,52], compared with RA cases 
and controls. Rates of thromboembolism increase substantially with age, and also vary 
ethnically. Whilst caution is required when comparing these studies (owing to heterogeneity 
in the types of individuals enrolled and the manner in which RA was diagnosed), overall the 
balance of evidence suggests that in the general population and non-RA controls there are 1-4 
thromboembolic events per 1,000 patient years. In RA, thromboembolic risks increase to 3-8 
per 1,000 patient years. The impact of biologics and DMARDs on disease risk appears 
minimal, though corticosteroids may increase risks especially when treatment is initiated. Our 
previously stated estimate of the rate of thromboembolic events with 4mg baricitinib in trials 
of active RA (5 per 1,000 patient years) therefore falls within the expected range observed in 
RA patients irrespective of their treatment. 
 
Challenges in Identifying Drug Risks in Rheumatoid Arthritis 
It is important to consider the risks posed with novel drugs against those posed with existing 
treatments. None of the drugs used in RA is completely safe. Even paracetamol, which is 
widely used by many patients with RA, is associated with an increased overall mortality and 
a range of adverse events, with myocardial infarctions in some observational studies [53]. 
Historic studies have highlighted serious problems, including deaths, associated with long-
established anti-rheumatic drugs, particularly NSAIDs and corticosteroids [54].  
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Methotrexate, which is the dominant DMARD in RA, can cause deaths due to bone marrow 
failure [55], interstitial lung disease [56] and inadvertent over-dosage [57]. Other DMARDs 
can also cause drug-related mortality. However, these risks must be weighed against the 
extensive evidence that effective treatment with methotrexate reduces overall mortality [58]. 
Although the risks of serious adverse events and excess mortality were a concern when 
biologics were introduced, there is robust evidence that they have overall beneficial effects 
with minimal evidence of excess mortality from receiving them [59]. 
 
Severe adverse reactions and deaths are relatively uncommon with anti-rheumatic drugs, 
including JAK inhibitors. However, the sizes of the clinical trials needed to define efficacy 
are insufficient to fully assess all the potential harms. In addition, trials often exclude patients 
who are older, frail, or have significant comorbidities; it is these individuals that are more 
likely to have significant adverse reactions to drugs but also more likely to suffer from 
thromboembolic disease. There are also major difficulties in distinguishing between the 
effects of RA and the impact of other drug treatments. In the case of biologics, establishing 
independent, long-term observational registries, was a crucial step in ensuring biologic 
treatment risks were not excessive. Similar approaches may be needed with new small 
molecule agents, like JAK inhibitors. 
 
Conclusions 
The publically available data suggests that in trials of baricitinib in RA there have been 
numerically more thromboembolic events in patients receiving active than control treatment, 
though there are too few patients to know if this difference is statistically significant. 
However, the risk of thromboembolism is small (about 5 events per 1,000 patient years) and 
appears comparable to the background risk observed in patients with RA (about 3-8 per 1,000 
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patient years). If one JAK inhibitor increases thromboembolic risks it is likely that this is a 
class effect and other JAK inhibitors may show risks. The observational study by Verden et al 
[24] suggests there may indeed be a general effect of JAK inhibitors on thromboembolic 
disorders, though there are ongoing uncertainties about its precise nature. 
 
Concerns about thromboembolic risks with baricitinib are likely to have contributed to the 
FDA deciding to delay its approval. Such decisions are beyond academic review as regulators 
need to consider potential as well as actual risks. Uncertainties about risks with new 
treatments can be minimised by delaying approval so that further data can be accrued, though 
this has the disadvantage of also delaying patients accessing effective new treatments. 
 
Manufacturers will undoubtedly wish to ensure full details of thromboembolic risks with JAK 
inhibitors are in the public domain as soon as possible. However, providing this information 
is unlikely to resolve uncertainties about the risks involved. The number of thromboembolic 
events will be small, patients enrolled in trials will not be representative of all RA patients 
likely to receive JAK inhibitors, and the amount of observational data outside trials is 
relatively limited. There is consequently a need for further large observational studies to 
accurately quantify thromboembolic risks attributable to new and existing drugs used to treat 
RA, and differentiate these from risks attributable to RA itself or its comorbidities. Until 
more information becomes available clinicians prescribing JAK inhibitors for RA ought to 
use these drugs cautiously in patients with pre-existing potential thromboembolic risks. 
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Table 1 Thromboembolic Events, Deaths and Serious Adverse Events in Baricitinib Trials  
With Comparative Deaths And Serious Adverse Events From Systematic Review Of Tofacitinib 
 
Authors Trial Year Size Duration Thromboembolic Events Deaths Serious Adverse Events 
Baricitinib 
     Placebo Baricitinib 4mg Placebo Baricitinib 2mg 
Baricitinib 
4mg Placebo 
Baricitinib 
2mg 
Baricitinib 
4mg 
Fleischmann 
et al [13] 
RA-
Begin 2017 588 12 months 
Death from 
pulmonary 
embolism 
- 3/210 - 0/374 20/201 - 29/374 
Taylor et al 
[14] 
RA-
Beam 2017 1307 12 months - Thrombophlebitis 1/488 - 3/487* 22/488 - 23/487** 
Dougados et 
al [15] 
RA-
Build 2017 684 6 months 
- Pulmonary 
embolisma 2/228 0/229 0/227 11/228 6/229 12/227 
Tanaka et al 
[16] Phase 2 2016 145 3 months No 
thromboembolic 
events reported 
- 
0/49 0/24 0/24 1/49 1/24 0/24 
Keystone et 
al [17] Phase 2 2015 301 6 months 0/98 0/52 0/52 3/98 3/52*** 0/52*** 
Genovese et 
al [18] 
RA-
Beacon 2016 527 6 months 0/176 0/174 1/177 13/176 7/174 18/177 
Total     - - 6/1240 (0.5%) 
0/479 
(0%) 
3/1341 
(0.2%) 
64/1240 
(5.2%) 
17/479 
(3.5%) 
82/1341 
(6.1%) 
Tofacitinib 
     - - Controls Recommended Dose High Dose Controls 
Recommended 
Dose High Dose 
Tarp et al 
[23] 
12 
trials 2009-14 5801 
2-24 
months - - 
2/1303 
(0.2%) 
6/1849 
(0.3%) 
3/2244 
(0.1%) 
72/1303 
(5.5%) 
126/1849 
(6.8%) 
130/2244 
(5.8%) 
 
*One death after switching from placebo to baricitinib 4mg 
** 6-month data 
*** 3-month data 
aOne additional pulmonary embolus in 28 day post-treatment follow up period 
Note: no data is provided about thromboembolic events in some arms of the baricitinib trials and the systematic review of adverse events by Tarp et al [23] 
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Table 2. Frequency Of Thromboembolism Events In The Normal Population And In Patients With Rheumatoid Arthritis 
 
Study Year Group Size Of Study Rate/1000 Patient Years 
White [49] 2003 Normal population From 6 major studies 1 
Heit [50] 2015 Normal populations From 11 major studies 1 to 2 
Holmqvist et al [30] 2012 Controls 207,271 controls 2 
Choi et al [31] 2013 Controls 95,776 controls 2 
Kim et al [32] 2013 Controls 920,697 controls 3 
Ogdie et al [37] 2017 Controls 1,225,571 controls 4 
Bacani et al [33] 2012 RA 813 cases 7 
Holmqvist et al [30] 2012 RA 45,490 cases 6 
Choi et al [31] 2013 RA 9,589 cases 3 
Kim et al [32] 2013 RA 92,827 cases 6 
Yusuf et al [34] 2015 RA 70,768 RA cases 5 
Kim et al [38] 2015 RA Biologics 5,920 cases 5 
Ogdie et al [37] 2017 RA DMARD 31,336 cases 8 
Kim et al [38] 2015 RA Methotrexate 17,614 cases 4 
Ogdie et al [37] 2017 RA No DMARD 20,426 cases 7 
 
DMARD=disease-modifying anti-rheumatic drug. 
